Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris

Ghent University Hospital (UZ)

Status and phase: Completed; Phase 2

Conditions: Vitiligo Vulgaris

Treatments: Drug: Application of pimecrolimus

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00372307

2003/275

Details and patient eligibility

About

Patients with vitiligo vulgaris are treated with Pimecrolimus twice a day during 6 months. After a baseline visit, patient returns for a control visit after 3 and 6 months of treatment. One reference lesion is clinically evaluated with pictures.

Sex: All

Ages: 6+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Active or stable vitiligo vulgaris
• lesions at head or neck + maximum 10% lesions at the rest of the body

Exclusion criteria

• Topica during last 2 weeks
• Photo(chemo)therapy during last 4 weeks
• Segmentary vitiligo

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)